Innovent Biologics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IVBXF research report →
About the company
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. It specializes in the discovery, advancement, and production of antibody-based drug candidates, with a strategic focus on therapeutic areas including cancer treatment (oncology), eye conditions (ophthalmology), immune system disorders (immunology), and metabolic ailments.
- CEO
- De-Chao Yu
- IPO
- 2019
- Employees
- 5,659
- HQ
- Suzhou, CN
Price Chart
- Market Cap
- $19.18B
- P/E
- 159.75
- P/S
- 10.10
- P/B
- 6.71
- EV/EBITDA
- 89.40
- Div Yield
- 0.00%
- Gross Margin
- 76.42%
- Op Margin
- 5.63%
- Net Margin
- 6.24%
- ROE
- 4.82%
- ROIC
- 2.39%
- Revenue
- $12.70B · 34.85%
- Net Income
- $792.57M · 937.54%
- EPS
- $0.47 · 908.95%
- Op Income
- $1.97B
- FCF YoY
- 2327.06%
- 52W High
- $15.12
- 52W Low
- $9.10
- 50D MA
- $10.32
- 200D MA
- $10.88
- Beta
- 0.20
- Avg Volume
- 5.39K
Get TickerSpark's AI analysis on IVBXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our IVBXF coverage
Recent articles, reports, and earnings notes.
No research on IVBXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IVBXF report →Similar companies
Peers in the same neighborhood.